Abstract
Background Real-time reverse transcription polymerase chain reaction (RT-PCR) targeting select genes of the SARS-CoV-2 RNA has been the main diagnostic tool in the global response to the COVID-19 pandemic. However, the diagnostic accuracy of the test has not been studied systematically outside of the laboratory setting. The aim of this study is to provide estimates of the diagnostic sensitivity and specificity of the RT-PCR test developed by China CDC.
Methods The study design is a secondary analysis of published findings on 1014 patients in Wuhan, China, of whom 601 tested positive and 413 were negative for COVID-19. Sensitivity and specificity were reconstructed using a Bayesian approach from probabilistic knowledge of the diagnostic errors. Predictive values of the test were calculated, resulting in estimates for the number of confirmatory tests that are needed for establishing the presence or absence of COVID-19, depending on the prior probability of a patient having the disease.
Results The sensitivity of the RT-PCR diagnostic test was estimated to be 0.777 (95% CI: 0.715, 0.849), while the specificity was 0.988 (95% CI: 0.933, 1.000). The confidence intervals include sampling error in addition to the error due to probabilistic knowledge of the data.
Discussion The Chinese version of the RT-PCR test had a conspicuous rate of false negative results, likely missing between 15% and 29% of patients with COVID-19. For a patient with a prior probability of COVID-19 greater than 18%, at least two negative test results would be needed to lower the chances of COVID-19 below 5%. Caution is advised in generalizing these findings to other versions of the RT-PCR test that are being used in diverse geographic regions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Published data were used in this study.
